Pay in 4 interest-free payments of $5.99 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Retatrutide vs tirzepatide vs semaglutide Category Receptor targets Retatrutide GLP-1 + GIP + Glucagon (triple) Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only (single) Category Half-life Retatrutide ~6 days Tirzepatide ~5 days Semaglutide ~7 days Category Dose frequency Retatrutide Once weekly Tirzepatide Once weekly Semaglutide Once weekly Category Max studied dose Retatrutide 12 mg/week Tirzepatide 15 mg/week Semaglutide 2.4 mg/week Category Peak weight loss in trials Retatrutide -28.7% at 68 weeks (Phase 3 TRIUMPH-4) Tirzepatide -22.5% at 72 weeks (SURMOUNT-1) Semaglutide -15.8% at 68 weeks (STEP-1) Category FDA status (June 2026) Retatrutide Investigational, Phase 3 Tirzepatide Approved (obesity + T2D) Semaglutide Approved (obesity + T2D) Category Liver fat Retatrutide Up to 82% reduction (Phase 2 substudy) Tirzepatide Significant reduction Semaglutide Moderate reduction Category Unique angle Retatrutide Triple agonism may raise energy expenditure via glucagon pathway Tirzepatide Dual agonism balances effect and tolerability Semaglutide Longest clinical track record
A second common mutation in the methylenetetrahydrofolate reductase gene: an additional risk factor for neuraltube defects
Reduced Inflammation: Hence, the anti-inflammatory property of these peptides should be further investigated to understand some of their potent mechanisms in managing chronic inflammatory conditions and general tissue health
Nanotechnology lighting the way for gene therapy in ophthalmopathy: from opportunities toward applications
Vi anvnder cookies fr att underltta din anvndning av webbplatsen, frbttra vra produkter, skrddarsy dem efter dina behov och visa dig relevant personanpassad och icke-personanpassad reklam
US$ 24.80
US$ 27.04
US$ 21.93
US$ 26.96
US$ 27.46
US$ 27.93
US$ 21.05
US$ 28.34
US$ 29.50
